TORONTO, Sept. 17, 2014 /CNW/ - SQI Diagnostics Inc. (TSX-V: SQD) (OTCQX: SQIDF), a life sciences company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that its common shares have been approved for trading in the United States on the OTCQX marketplace ("OTCQX"). Trading is expected to commence on September 17, 2014 on the OTCQX under the symbol SQIDF. The Company will continue to trade on the TSX Venture Exchange under its existing symbol SQD.
"We are pleased to be traded on the OTCQX marketplace," said Andrew Morris, Chief Executive Officer of SQI Diagnostics Inc. "Trading on the OTCQX will help increase awareness of SQI in the U.S investment community and is an important step for SQI's continued growth."
The OTCQX marketplace is for established, investor-focused U.S. and global companies. To qualify for OTCQX, companies must meet high financial standards, demonstrate compliance with U.S. securities laws, be current in their disclosure, and be sponsored by a professional third-party advisor. Designed for investor-focused companies, OTCQX ensures that investors and brokers have the quality of information that's necessary to intelligently analyze, value, and trade their securities. U.S. investors can find information and Real-Time Level 2 quotes for the Company on www.otcmarkets.com. Dorsey & Whitney LLP will act as the Company's Principal American Liaison on the OTCQX marketplace.
About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics. The Company's proprietary microarray tests and fully-automated systems are designed to simplify protein and antibody testing workflow, increase throughput, reduce costs and provide excellent data quality. For more information, please visit www.sqidiagnostics.com.
This news release contains certain forward-looking statements, including, without limitation, statements containing the words "will", "expects", "intends" and other similar expressions which constitute "forward-looking information" within the meaning of applicable securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to risks related to the timing for the commencement of trading on the OTCQX, the increased awareness by the U.S. investor community of the Company, our continued listing on both the TSX Venture Exchange and the OTCQX, the failure to obtain necessary regulatory approvals, general economic and market segment conditions, and international risk and currency exchange, agreements and future agreements to sell our products, the acceleration of our revenue ramp, general economic and market segment conditions. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company's ongoing filings with the securities regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: SQI Diagnostics Inc.
For further information: Chief Executive Officer, Andrew Morris, 416.674.9500 ext. 229, email@example.com